Bendamustine

In the US, Bendamustine (bendamustine systemic) is a member of the drug class alkylating agents and is used to treat Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma.

US matches:

• Bendamustine


• Bendamustine Intravenous


• Bendamustine Hydrochloride

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01AA09

CAS registry number (Chemical Abstracts Service)

0016506-27-7

Chemical Formula

C16-H21-Cl2-N3-O2

Molecular Weight

358

Therapeutic Category

Antineoplastic agent

Chemical Names

1H-Benzimidazole-2-butanoic acid, 5-[bis(2-chloroethyl)amino]-1-methyl-

5-[bis(2-chloroethyl)amino]-1-methyl-2-benzimidazolebutyric acid (WHO)

Foreign Names

• Bendamustinum (Latin)
• Bendamustin (German)
• Bendamustine (French)
• Bendamustina (Spanish)

Generic Names

• CIMET 3393 (IS)
• IMET 3393 (IS)
• Bendamustine hydrochloride (OS: USAN, JAN)
• NSC 138783 (IS)
• SDX 105 (IS)
• SyB L-0501 (IS)
• UNII-9266D9P3PQ (IS)

Brand Names

• Ribomustin
  Fujisawa, Bulgaria; Mundipharma, Switzerland; Mundipharma, Germany; Thymoorgan, Bulgaria



• Treanda
  Cephalon, United States

International Drug Name Search

Glossary

IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.